Previous 10 | Next 10 |
Vertigo3d/E+ via Getty Images Richard Branson made it into space. Beating Amazon's (AMZN) Jeff Bezos, who is scheduled to make his flight later this month, Virgin Galatic (SPCE) launched a fully crewed spaceflight over the weekend, including its billionaire founder Branson onboard. Disney (DI...
Tempest Therapeutics (TPST) +141%.Mer Telemanagement Solutions (MTSL) +56%.Celldex Therapeutics (CLDX) +41% on early-stage data for CDX-0159 in skin condition.SGOCO Group (SGOC) +38%.Antelope Enterprise Holdings (AEHL) +30%.Cemtrex (CETX) +19%.Carver Bancorp (CARV) +15%.Park City Gr...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader, and I hope you had a good weekend. We’re kicking off the week with a look at the biggest pre-market stock movers for Monday! Source: f11photo/Shutterstock.com We’re seeing a lot o...
JuSun/iStock via Getty Images Celldex Therapeutics (CLDX) jumped ~35.4% in the post-market Friday after the company updated early-stage trial data for CDX-0159, indicating 95% complete response following a single dose in patients with two most common forms of chronic inducible urticaria,...
- 95% complete response rate after single dose of CDX-0159 - - Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief - - Median duration of response 77+ days in Cold Urticaria and 57+ days in Symptomatic Dermographism - - ...
After Celldex tumbled back in 2018, the stock has now moved beyond recovery. The company recently posted strong Phase 1 data for its chronic urticaria drug (CDX-0159). At 2021 ASCO, Celldex presented acceptable data for its cancer medicine (CDX-527). For further details see:...
Celldex Therapeutics (CLDX) remains one of our Top Picks for 2021 with the company delivering value creating data updates so far this year, explains Jay Silverman, a leading biotech expert and contributing editor to The Medical Technology Stock Letter. For further details see: Top Picks...
At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen (OCGN), Senseonics Holdings (SEN...
HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These data were presented in a...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...